An Extended Role of Continuous Flow Device in Pediatric Mechanical Circulatory Support

Ed Peng, Richard Kirk, Neil Wrightson, Phuoc Duong, Lee Ferguson, Massimo Griselli, Tanveer Butt, John J. O'Sullivan, Guy A. MacGowan, David Crossland, Stephan Schueler, Asif Hasan

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Background Mechanical circulatory support in the pediatric population is currently limited to pulsatile ventricular assist devices (VAD). In recent years, the use of durable, newer generation, continuous flow devices have increased substantially among adults with end-stage heart failure. We examined the extended role of this device in the pediatric population (aged less than 18 years). Methods Between 2010 and 2015, 12 patients (median age 7.1 years; range, 3.7 to 17.0; one third of patients were aged 5 years or less) received a HeartWare ventricular assist device (HVAD; HeartWare, Framingham, MA), 11 for cardiomyopathy and 1 for posttransplant rejection. Right VAD support (n = 5; 42%) was provided by a short-term device (Levitronix, Zurich, Switzerland). Results Overall, 1 patient died (day 638), 8 patients (67%) underwent transplantation, 1 patient (8.3%) recovered, and 2 patients (17%) remain on HVAD. The mean length of support was 150 days (range, 16 to 638). Four patients (33.3%) were discharged home (all left VAD). In the left VAD group (n = 7), 3 patients subsequently received transplants (days 185, 201, and 234, respectively), 1 recovered (day 149), 1 died (day 638), 1 remained on HVAD (day 198), and 1 needed conversion to biventricular assist device (BIVAD [day 73]). In the BIVAD group (n = 5), right VAD was weaned in 3 (60%), all subsequently received transplants, and 2 remained on BIVAD support until transplant (days 16 and 17, respectively). One BIVAD patient required conversion to central cannulation for longer-term support. Four BIVAD patients (80%) were in Interagency Registry for Mechanically Assisted Circulatory Support level 1 before VAD compared with 2 (29%) in the left VAD group (p = not significant). The actuarial survival rate was 100% at 1 year with no neurologic events. Conclusions The third-generation, continuous flow device can provide durable support in the pediatric population. The selection strategy for patients who benefit most from the device continues to evolve. It is anticipated that a smaller design in the future will benefit an even wider pediatric population with heart failure.

Original languageEnglish (US)
Pages (from-to)620-627
Number of pages8
JournalAnnals of Thoracic Surgery
Volume102
Issue number2
DOIs
StatePublished - Aug 1 2016

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'An Extended Role of Continuous Flow Device in Pediatric Mechanical Circulatory Support'. Together they form a unique fingerprint.

  • Cite this

    Peng, E., Kirk, R., Wrightson, N., Duong, P., Ferguson, L., Griselli, M., Butt, T., O'Sullivan, J. J., MacGowan, G. A., Crossland, D., Schueler, S., & Hasan, A. (2016). An Extended Role of Continuous Flow Device in Pediatric Mechanical Circulatory Support. Annals of Thoracic Surgery, 102(2), 620-627. https://doi.org/10.1016/j.athoracsur.2016.02.013